Pathfinders in Biopharma

33 Episodes

1. The M&A Pool Set to Accelerate Biotech Innovation

   Published: 4/3/2024
2. How PIPEs finally unblocked biotech’s funding flows

   Published: 3/29/2024
3. Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back

   Published: 3/7/2024
4. Will the Biotech Rebound Run into Pricing Policy Obstacles?

   Published: 2/27/2024
5. Few IPOs but plenty of follow-on for biotech in 2023

   Published: 1/22/2024
6. U.S. Outlook: Will the US economy achieve a soft landing in 2024?

   Published: 12/29/2023
7. Raising Venture Capital: A New Playbook for A New Era in Biotech

   Published: 11/22/2023
8. ECM: Robust End to Year, Despite Previous Volatility

   Published: 10/31/2023
9. Biotech Halftime Report: A Winding Road Ahead

   Published: 9/26/2023
10. The Urgent Need to Address the Youth Mental Health Landscape

    Published: 8/17/2023
11. Website Traffic Reveals Biopharma Sales Trends

    Published: 8/7/2023
12. When to Call it Quits: VCs Making Tough Decisions in a Tough Market

    Published: 7/13/2023
13. How Biotech M&A is Redefining the Strategic Landscape

    Published: 6/23/2023
14. Healthcare Should Get Ready for ‘Fast and Furious’ M&A

    Published: 6/8/2023
15. Innovation and Growth: Key Ingredients to Healthcare M&A

    Published: 6/7/2023
16. Biotech M&A Booms, But Have Buyouts Reached a Tipping Point?

    Published: 6/2/2023
17. Global Blood Therapeutics Commitment to Sickle-Cell Innovation

    Published: 5/22/2023
18. Is This the Breakthrough Moment for Genetic Medicine?

    Published: 4/13/2023
19. The Hidden Revolution Set to Turn US Healthcare on its Head

    Published: 1/26/2023
20. The Big Picture for Biotech

    Published: 12/13/2022